- Home
- CPHC vs LUNG Comparison
CPHC vs LUNG Comparison
Compare CPHC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPHC | LUNG |
|---|---|---|
| Founded | 1994 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.3M | 72.2M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPHC | LUNG |
|---|---|---|
| Price | $15.31 | $1.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | 2.1K | ★ 341.2K |
| Earning Date | 03-09-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $59,099,604.00 | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $14.39 | $1.31 |
| 52 Week High | $21.61 | $9.37 |
Technical Indicators
Market Signals| Indicator | CPHC | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 29.20 |
| Support Level | $15.05 | $1.38 |
| Resistance Level | $15.95 | $1.56 |
| Average True Range (ATR) | 0.29 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 78.43 | 8.33 |
Price Performance
Historical ComparisonAbout CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.